Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:52:37 EDT Wed 15 May 2024
Enter Symbol
or Name
USA
CA



Q:CRBP - CORBUS PHARMACEUTICALS HOLDINGS IN - http://www.corbuspharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRBP - Q0.142.00·44.990.244.14+1.152.7251.811,0582,35443.52  46.00  43.5149.8699  3.033418:13:14May 0915 min RT 2¢

Recent Trades - Last 10 of 2354
Time ETExPriceChangeVolume
18:13:14Q44.881.891
17:43:09Q44.881.891
16:44:19Q42.00-0.992
16:44:19Q41.94-1.057
16:00:10Q44.141.15183
16:00:09Q44.141.1578
16:00:01Q44.141.1518
16:00:01Q44.141.15100
16:00:01Q44.141.15100
16:00:01Q44.141.1514

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-09 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
2024-05-07 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-01 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
2024-04-24 16:05U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
2024-04-02 08:00U:CRBPNews ReleaseCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
2024-03-12 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
2024-03-06 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
2024-02-28 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
2024-02-06 09:51U:CRBPNews ReleaseCorbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-02-02 16:01U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-01-31 09:20U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Pricing of Public Offering
2024-01-30 18:55U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Proposed Public Offering
2024-01-29 06:58U:CRBPNews ReleaseInvestors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
2024-01-26 07:30U:CRBPNews ReleaseCRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
2024-01-23 08:00U:CRBPNews ReleasePhase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
2024-01-09 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti- Ž ±v Ž ²8 monoclonal antibody (CRB-601)
2023-12-18 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
2023-11-07 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-02 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its ‚  Anti- Ž ±V Ž ²8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
2023-10-17 08:00U:CRBPNews ReleaseCorbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023